Posters will be presented Saturday through Tuesday from 12:30 pm - 2:45 pm

Symposia

Sunday Morning (9:30 am - 12:00 noon)

Hypocretin (Orexin) and GHB:  Molecular Mechanisms to Clinical Therapeutics
Sponsored by the Divisions for Behavioral Pharmacology and Systems & Integrative Pharmacology)
Chairs:  Charles P. France and Luis de Lecca
Convention Center, Room 5A

Sleep/wake, energy homeostasis, and orexin/hypocretin neuropeptides
  Masashi Yanagisawa, Univ. of Texas Southwestern Med. Ctr.

Narcolepsy and hypocretin
   Emmanuel Mignot, Stanford Univ.

Hypocretin, GHB and narcolepsy: Clinical perspectives
   Gert J. Lammers, Leiden Univ. Med. Ctr., Leiden, The Netherlands

Preclinical pharmacology of GHB
   Wouter Koek, Univ. of Texas Hlth. Sci. Ctr. at San Antonio

Glucuronosyl Transferases: Their Role in Drug Interactions and Toxicity
Chairs:  Rory P. Remmel and Timothy S. Tracy
(Sponsored by the Divisions for Drug Metabolism, Pharmacology Education, and Toxicology)
Convention Center, Room 4

Drug-drug interactions involving glucuronidation: An unrecognized phenomenon
    Rory P. Remmel, Univ. of Minnesota Col. of Pharm.

Regulation of UGT's
   Robert H. Tukey, UCSD

Role of UGT polymorphisms in drug and diet effects and cancer risk
    Johanna W. Lampe, Fred Hutchinson Cancer Res. Ctr.

Modulation of toxicity via glucuronidation
    Philip C. Smith, Univ. of North Carolina at Chapel Hill

Ray Fuller Symposium
Neurotransmitter Transporters: Signaling in Flux
(Sponsored by the Division for Neuropharmacology)
Chair:  Randy D. Blakely
Convention Center, Room 2

Molecular biophysics of amphetamine action
    Aurelio A. Galli, Vanderbilt Univ.

Phosphorylation based regulation of biogenic amine transporters
    Sammanda Ramamoorthy, Medical Univ. of South Carolina

Molecules in motion: The multiple mechanisms that regulate GABA transporter function
   Michael W. Quick, USC

Protein-protein interactions during assembly and trafficking of glutamate transporters
   Michael B. Robinson, Univ. of Pennsylvania

Short Course:  Cardiac Electrophysiology and Implications for Drug Development
Chair:  Benedict R. Lucchesi
Convention Center, Room 3

Cardiac electrophysiology and arrhythmogenesis
  Benedict R. Lucchesi, University of Michigan

 

Introduction to the electrocardiogram
  Peter S. Fischbach, University of Michigan

 

Drug-induced malignant ventricular tachycardia (TdP): A major safety pharmacology issue in drug selection, development and registration
  Icilio Cavero, Senior Research Advisor, Italy

 

Web Links

Sunday Afternoon (3:00 pm - 5:30 pm)

Social Structure and Influences on Drug Actions
Chairs:  Michael A. Nader and Klaus A. Miczek
(Sponsored by the Divisions for Behavioral Pharmacology, Neuropharmacology, and Systems & Integrative Pharmacology)
Convention Center, Room 5B

Epidemiologically based prevention research on drug abuse
     Sheppard G. Kellam, American Inst. for Res., Baltimore, MD

The physiology of social dominance: Individual differences in the functions of the HPA axis
     Robert M. Sapolsky, Stanford Univ. Sch. of  Med.

Individual differences in vulnerability and resilience to early stress effects on adult CSF monomine concentrations, social behavior, and alcohol consumption
     Allyson J. Bennett, Wake Forest Univ. Sch. of Med.

Individual differences in dopamine and serotonin receptor function, behavioral and reinforcing effects of drugs in socially housed monkeys
     Michael A. Nader, Wake Forest Univ. Sch. of Med.

Aggressive vs. submissive experiences: Differential cocaine self-administration and mesocorticolimbic cellular activation
     Klaus A. Miczek, Tufts Univ.

HDL Therapy: The New Frontier for the Treatment of Cardiovascular Diseases
Chairs:  Charles L. Bisgaier and Roger S. Newton
(Sponsored by the Division for Cardiovascular Pharmacology)
Convention Center, Room 3

Structural features and function properties of high density lipoproteins: Relevance to human cardiovascular disease
     H. Bryan Brewer, NHLBI, NIH

Discovery, history and evolution of Apo A-l Milano: A variant protein with beneficial effects
     Cesare R. Sirtori, Univ. of Milan

HDL: A modulator of inflammation and a therapy for cardiovascular diseases
     Prediman K. Shah, Cedars-Sinai Med. Ctr.

Cardioprotective effects of Apo A-1Milano/phospholipid (ETC-216) complexes
     Marta Marchesi, Univ. of Milan

Effect of recombinant Apo A-1Milano (ETC-216) on coronary atherosclerosis in patients with acute coronary syndromes
     Steven Nissen, Cleveland Clinic Fndn.

Protein Modification during Oxidative Injury
Chairs:  Daniel C. Lieber and Serrine S. Lau
(Sponsored by the Divisions for Toxicology and Drug Metabolism)
Convention Center, Room 5A

Application of LC-MS methods to identify protein targets of reactive electrophiles generated by lipid peroxidation
     Daniel C. Liebler, Vanderbilt Univ. Sch. of Med.

Chemistry of adduction of proteins by the prototypical electrophiles 4-hydroxynonenal and 4-oxononenal
     Lawrence M. Sayre, Case Western Res. Univ.

Nitric oxide-induced protein modifications: Challenges of analysis    
   Steven R. Tannenbaum, MIT

Identification of chemical adduction to target proteins and the impact on biological function
     Serrine S. Lau, Univ. of Arizona Col. of Pharm.

Functional Selectivity of Receptor Signaling:  Epiphenomenon or New Opportunity for Drug Discovery?
Chair: David R. Sibley
(Sponsored by the Divisions for Neuropharmacology and Molecular Pharmacology)
Convention Center, Room 2

Ligand-specific cellular signaling profiles at the 5-HT2C receptor
     William P. Clarke, Univ. of Texas Hlth. Sci. Ctr. at San Antonio

Regulation of GPCRs by endocytic membrane trafficking: Novel mechanisms and potential therapeutic targets
     Mark von Zastrow, UCSF

What is the molecular basis for functional selectivity of drugs at the 5-HT2A receptor?
     David E. Nichols, Purdue Univ. Sch.of Pharm. & Pharmaceut. Sci.

Functional selectivity of dopamine receptor ligands predict novel behavioral effects:  Examples from the lab to the clinic
     Richard B. Mailman, Univ. of North Carolina at Chapel Hill Med. Sch.

Ligand specific conformational changes of GPCRs: Consequences for receptor signaling
     Brian K. Kobilka, Stanford Univ. Med. Ctr.

Refresher Course: Pharmacokinetics
Chair:  Juan J.L. Lertora

(Sponsored by the Division for Pharmacology Education)
Convention Center, Room 4

So, you’re teaching Pharmacokinetics for the first time, or want a refresher of the principles?   Dr. Juan Lertora, a clinical pharmacologist from Tulane, will demonstrate tips and techniques for efficiently teaching this topic to medical students.  Audience discussion will solicit other successful approaches. Teaching materials will be made available.

Monday Morning (9:30 am - 12:00 noon)

Role of Neuroinflammation in Neuropathic Pain
Chair:  Michael R. Brandt
(Sponsored by the Divisions for Drug Discovery, Drug Development & Regulatory Affairs; Behavioral Pharmacology; and Neuropharmacology)
Convention Center, Room 5A

The increasingly recognized role of neuroinflammation in neuropathic pain; an introduction to the symposium
     Robert R. Myers, UCSD

Role of CB2 receptors in conditions of neuropathic pain
     T. Philip Malan, Jr., Univ. of Arizona Col. of Med.

Central cytokines as drug targets for the treatment of neuropathic pain
     Raymond W. Colburn, Johnson & Johnson Pharmaceut. R&D, LLC

Cytokine polymorphisms and the risk of persistent neuropathic pain: Therapeutic implications
     Mitchell B. Max, NIDCR, NIH

 

Dynamic changes of dorsal root ganglion gene expression in a rat model of neuropathic pain
     Katherine W. Figueroa, UCI

C-Reactive Protein and Cardiovascular Disease:  Epiphenomenon or Therapeutic Target?
Chairs:  Mark B. Pepys and Benedict R. Lucchesi
(Sponsored by the Division for Cardiovascular Pharmacology)
Convention Center, Room 3

Structure, function and pathobiology of CRP:  A therapeutic target in cardiovascular disease?
     Mark B. Pepys, Royal Free and Univ. Col. Med. Sch., London, U.K

CRP and cardiovascular disease: A critical review of the epidemiological evidence
     Gordon D.O. Lowe, Glasgow Royal Infirmary, Glascow, U.K.

CRP is a valuable risk marker for cardiovascular disease
     Peter Libby, Harvard Med. Sch.

Role of CRP in pathogenesis of atherosclerosis
     Edward T.H. Yeh, Univ. of Texas at Houston

CRP and acute coronary syndromes
     Attilio Maseri, Vita-Salute San Raffaele Univ., Milan, Italy

 

Role of Xenobiotic Metabolizing Enzymes in the Homeostatic Control of Endogenous Substrates
Chair: Robert L. Haining
(Sponsored by the Division for Drug Metabolism)
Convention Center, Room 4

Metabolism of endogenous substrates by xenobiotic metabolizing enzymes
     Robert L. Haining, West Virginia Univ. Sch. of Pharmacy

Arachadonic acid metabolism: Bench to bedside
     Jorge H. Capdevila, Vanderbilt Univ.

Regulation of cholesterol homeostasis by cytochromes P450
     Irina A. Pikuleva, Univ. of Texas Med. Br. at Galveston

Endogenous ligands of the xenobiotic pregnane X receptor
     Joyce J. Repa, Univ. of Texas Southwestern Med. Ctr.

PXR induces CYP27A1 in the intestine: A cross talk between drug metabolism and cholesterol homeostasis
     Tiangang Li, Northeastern Ohio Univ. Col. of Med. 

Pathways Illuminated:  Visualizing Cell Signaling
Chair: Alexandra C. Newton
(Sponsored by the Division for Molecular Pharmacology)
Convention Center, Room 2       

Visualizing signaling by kinases B and C in cells
     Alexandra C. Newton, UCSD

Microanalytical tools to track cellular signaling
     Nancy L. Allbritton, UCI

The molecular architecture of signal transduction complexes
     John D. Scott, Oregon Hlth. & Sci. Univ.

Spatiotemporal dynamics of intracellular signaling
     Atsushi Miyawaki, Riken Brain Science Inst., Saitama, Japan

Visualization of protein kinase C activity in real time in live cells
     Lisa L. Gallegos, UCSD

How to Talk about Pharmacology to the Public
Chair:  Patangi K. Rangachari
(Sponsored by the Division for Pharmacology Education)
Convention Center, Room 5B

Teaching about drugs in high schools
     Nancy Kellogg, Brawley Union High Sch., Brawley, CA

The media's role in disseminating information
     Bob Carty, CBC Radio One, Toronto

Out-reach possibilities
     Jack W. Strandhoy, Wake Forest Univ. Sch. Med.

Lost in translation: Getting students to think about communication
  Patangi K. Rangachari, Univ. of Calgary Med. Sch., Calgary, Canada

Monday Afternoon (3:00 pm - 5:30 pm)

Heterotrimeric G-Proteins in Oncogenesis and Metastasis
Chair:  Patrick J. Casey
(Sponsored by the Division for Molecular Pharmacology)
Convention Center, Room 2

Introduction
     Patrick J. Casey, Duke Univ. Med. Ctr.

The role of G12 family of heterotrimeric G proteins in breast cancer metastasis
     Patrick Kelly, Duke Univ. Med. Ctr.

Regulation of lymphocyte migration by G protein-coupled receptor signaling
     John H. Kehrl, NIAID, NIH

Moleuclar mechanisms of bone metastases: Rationale for targeting the endothelin axis
     Theresa A. Guise, Univ. of Virginia

Cellular and biological functions of G12/G13
     Stefan Offermanns, Univ. of Heidelberg

New Pharmacological Targets in Alzheimer's Therapeutics
Chair:  A. Claudio Cuello
(Sponsored by the Division for Neuropharmacology)
Convention Center, Room 3

Novel therapeutic targets in Alzheimer's disease
      A. Claudio Cuello, McGill Univ.

The inhibition of beta-secretase as a therapeutic objective in Alzheimer's disease
     Martin Citron, Amgen, Inc.

The inhibition of gamma-secretase as a therapeutic objective in Alzheimer's disease
     Michael S. Wolfe, Brigham and Women's Hosp./Harvard Univ.

Nonsteroidal anti-inflammatory drugs  in the experimental treatment of Alzheimer's disease
     Sascha B. Weggen, Johannes Gutenberg-Univ., Mainz, Germany

Vaccination versus passive immunotherapy in the treatment of Alzheimer's
     David G. Morgan, Univ. of South Florida

Inference of Biological Regulatory Networks
Chair:  Kenneth S. Ramos
(Sponsored by the Divisions for Systems & Integrative Pharmacology, Molecular Pharmacology, and Toxicology)
Convention Center, Room 5B

From expression to function: Data integration for the interpretation of 'omics data
  John Quackenbush, Inst. for Genomic Res., Rockville, MD

Gene-gene interactions regulated by ligands of the aryl hydrocarbon receptor
  Kenneth S. Ramos, Univ. of Louisville

The tumor suppressor functions of tuberin integrate cell cycle regulation and DNA repair
  Serrine S. Lau, Univ. of Arizona Col. of Pharmacy

Metabolomics to predict physiology and toxicology
  Bruce D. Hammock, UC-Davis

A systems/networks approach to modeling the DNA damage response
  Trey G. Ideker, UCSD

Tuesday Morning (9:30 am - 12:00 noon)

Developmental Expression of Drug Metabolizing Enzymes and Impact on Pediatric Clinical Pharmacology
Chair: Jeffrey C. Stevens
(Sponsored by the Divisions for Drug Metabolism and Systems & Integrative Pharmacology)
Convention Center, Room 4

FMO developmental expression
     Ronald N. Hines, Med. Col. of Wisconsin

Human CYP3A ontogeny
     Jeffrey C. Stevens, Pfizer, Inc.

Development and drug clearance: Clinical expression of ontogeny and pharmacogenetics
     Gregory L. Kearns, Univ. of Missouri, Kansas City

UGT development
     Christian C. Strassburg, Hannover Med. Sch., Hannover, Germany

Pharmacogenomics:  Perception and Reality
Chairs: Laura K. Nisenbaum and Joan M. Lakoski
(Sponsored by the Committee on Women in Pharmacology)

Convention Center, Room 3

Pharmacogenomics in prescribing and drug development
Alastair J.J. Wood, Vanderbilt Univ. Sch. of Med.

Drug uptake transporters in the intestine and brain: New insights to their expression and function
  Richard B. Kim, Vanderbilt Univ. Sch. of Med.

Drug target pharmacogenetics: Focus on beta-blockers
  Julie A. Johnson, Univ. of Florida

Applications to drug discovery and development
  Sandra Kirkwood, Eli Lilly and Co.

Human genetic variation and complex traits
  Kelly A. Frazer, Perlegen Sciences, Inc., Mountain View, CA

          
G-Protein-Coupled Receptor Oligomerization:  Biology and Drug Discovery
Chair:  Kendall J. Blumer
(Sponsored by the Division for Molecular Pharmacology)
Convention Center, Room 2

G-protein-coupled receptor oligomerization and signaling
     Kendall J. Blumer, Washington Univ. Sch. of Med.

Cell biology of G protein-coupled receptor oligomerization
     Michel Bouvier, Univ. of Montreal Fac. of Med., Montreal, Canada

Frizzled receptor oligomerization in human disease
     Stephane Angers, Univ. of Washington

Chemokine receptor oligomerization and lymphocyte recruitment
     Carlos Martinez-A., Univ. of Cantoblanco, Madrid, Spain

GPCR oligomerization and drug discovery
     Susan R. George, Univ. of Toronto

Olfactory and β₂-adrenergic receptors  form stable cell-surface complexes
     Chris Hague, Emory Univ. Sch. of Med.

Epigenetic Reprogramming of Cancer Cells
Chair:  Bernard W. Futscher
(Sponsored by the Division for Toxicology)
Convention Center, Room 5B

Keynote Lecture: Background and historical perspective of epigenetics and cancer treatment
  Peter A. Jones, USC

The promise of DNA methylation markers in cancer prognostication
  Peter W. Laird, USC

Tumor specific patterns of aberrant DNA methylation
  Joseph F. Costello, UCSF

Histone acetylation/deacetylation – Therapeutic opportunities
     Bernard W. Futscher, Univ. of Arizona Col. of Pharm.

Epigenetic modification – the clinical experience
  Steven D. Gore, Johns Hopkins Univ. Sch. of Med.

   

Adolescent Drug Abuse: Long-Term Effects of Exposure of the Developing Brain to Drugs of Abuse

Chairs:  Robert N. Pechnick and Kathryn A. Cunningham
(Sponsored by the Divisions for Neuropharmacology, Behavioral Pharmacology and Systems & Integrative Pharmacology)
Convention Center, Room 5A

Introduction
  Robert N. Pechnick, Cedars-Sinai Med. Ctr.

Overview of concepts and issues in the study of the adolescent brain and drugs of abuse
   Linda P. Spear, SUNY-Binghampton

The effects of nicotine on adolescent brain.
     Frances M. Leslie, Univ. of California, Irvine

Adolescent exposure to stimulants
     Michela Marinelli, Rosalind Franklin Univ. of Med. & Sci./Chicago Med. Sch.

Teenagers and drug abuse
     Uma Rao, Univ. of Texas Southwestern Med. Ctr.

Short Course:  Lipid Signaling Pathways and Paradigms
Marriott Hotel, Marina E

Phosphatidylcholine metabolism
  Andrew J. Morris, Univ. of North Carolina at Chapel Hill

Phosphatidylinositol metabolism
  Michael Wakelam, Birmingham Univ. Med. Sch., Birmingham, UK

Sphingolipid metabolism
  Alfred H. Merrill, Jr., Georgia Inst. of Tech.

Eicosanoid metabolism
  Jilly Evans, Merck & Co.

Tuesday Afternoon (3:00 pm - 5:30 pm)

Decisions of Benefit vs. Risk:  QT Interval Prolongation by Non-Cardiac Drugs
Chairs:  Alan S. Bass and Peter K. Siegl
(Sponsored by the Divisions for Drug Discovery, Drug Development & Regulatory Affairs and Cardiovascular Pharmacology)
Convention Center, Room 3

Molecular basis for drug-induced torsades de pointes, its relationship to QT prolongation; who is at risk?
     Dan M. Roden, Vanderbilt Univ. Sch. of Med.

Strategy for the non-clinical testing of new drugs for the potential of eliciting torsades de pointes arrhythmia
     Alan S. Bass, Schering-Plough Res. Inst.

Strategies for the clinical evaluation of new drugs for the potential of eliciting torsades de pointes arrhythmia
     Borje Darpo, Daiichi Med. Res., London, UK

An integrated risk assessment: Benefit vs. risk of progressing a new drug to the marketplace
     Peter K. Siegl, Merck Res. Labs

Drug block of hERG channels: Reconciling pharmacophore and receptophore models    
    Michael C. Sanguinetti, Univ. of Utah

Wednesday Morning (8:30 am - 11:00 am) \   NOTE TIME CHANGE!

Mechanism of Tissue Selective Drug Action in the Cardiovascular System
Chair:  Terry D. Barrett
(Sponsored by the Division for Systems & Integrative Pharmacology and Cardiovascular Pharmacology)
Convention Center, Room 3 

Selectivity beyond receptor density
  Terry D. Barrett, Johnson & Johnson Pharmaceut. R&D

Mechanism for the selective action of PDE5 inhibition on the corpus cavernosum
     Donald H. Maurice, Queen's Univ. at Kingston

Ischaemia-selective antiarrhythmic drugs action and antiarrhythmic efficacy
     Michael J.A. Walker, Univ. of British Columbia

Tissue specific actions of structurally divergent calcium channel blocking agents
     David J. Triggle, SUNY at Buffalo Sch. of Pharm. and Pharmaceut. Sci.

Short talk selected from abstract

Lysophosphatidic Acid:  From Metabolite to Mediator to Medicine
Chairs:  Myron L. Toews and Kathryn E. Meier
(Sponsored by the Divisions for Molecular Pharmacology and Systems & Integrative Pharmacology)
Convention Center, Room 2 

Lysophosphatidic acid: A multi-functional lipid mediator
     Wouter H. Moolenaar, The Netherlands Cancer Inst.

Large and small molecules as probes of LPA biology
     Kevin R. Lynch, Univ. of Virginia

Development of selective ligands for LPA GPCRs
     Gabor J. Tigyi, Univ. of Tennessee, Memphis

A molecular modeling approach to identify LPA and S1P receptor subtype-selective pharmacophores
     Abby L. Parrill, Univ. of Tennessee, Memphis

LPA as a therapeutic target in cancer
     Gordon B. Mills, Univ. of Texas Hlth. Sci. Ctr. at Houston

 

Novel Insights into Myocardial Preconditioning:  From the Clinic to the Proteome

Chairs:  Steven P. Jones and Garrett J. Gross
(Sponsored by the Division for Cardiovascular Pharmacology)
Convention Center, Room 4

Clinical evidence for myocardial preconditioning
     Roberto Bolli, Univ. of Louisville Sch. of Med.

Mechanisms of opioid-induced preconditioning
     Garrett J. Gross, Med. Col. of Wisconsin

Proteomic identification of cardioprotective candidate proteins
     Jennifer E. van Eyk, Johns Hopkins Univ.

Opioid-induced cardioprotection involves cross-talk between K_ATP channels and the phosphatidylinositol-3 kinase (PI3k) pathways
     Eric R. Gross, Med. Col. of Wisconsin

Sphingosine 1-phosphate receptors provide protection against in vivo myocardial ischemia-reperfusion injury through regulation of Akt
     Christopher K. Means, UCSD

Molecular Library Approaches to CNS Drug Discovery
Chair:  Bryan L. Roth
(Sponsored by the Divisions for Neuropharmacology; Drug Discovery, Drug Development & Regulatory Affairs; and Molecular Pharmacology)
Convention Center, Room 5A

 Screening the receptorome reveals validated targets for CNS drug discovery
     Bryan L. Roth, Case Western Res. Univ. Med. Sch.

Allosteric potentiators of GPCRs as novel therapeutic agents for treatment of CNS disorders
     Jeffrey Conn, Vanderbilt Univ.

Targeting protein-protein interactions: Future or folly?
     Richard R. Neubig, Univ. of Michigan

Non-amines: Have we been too aminated?
     Bertha K. Madras, New England Primate Res. Ctr., Harvard Med. Sch.

Imaging amyloid in humans
     William Klunk, Univ. of Pittsburgh

         

Drug Metabolism Division Platform Session:  Biotransformation and Drug Transport
Chairs: Tim S. Tracy and David S. Riddick
Convention Center, Room 10

James R. Gillette Best Paper Awards and Selected Contributed Paper Presentations

Carrier-mediated Uptake of H2-receptor Antagonists by the Rat Choroid Plexus: Involvement of Rat Organic Anion Transporter 3
     H. Kusuhara, Univ. of Tokyo

Aerodigestive epithelial cell accumulation of the cancer preventive polyphenol ellagic acid – role of organic anion transporters
     Alex C. Whitley, Med. Univ. of South Carolina

Ontogeny Of Brain Mdr1a Expression: Implications For Cyclosporine A Neurotoxicity In Young Children
     Kerry B. Goralski, Dalhousie Univ.

Regulation of the multidrug resistance-associated protein 3 by bile acids
     Tanya C. McCarthy, Dalhousie Univ.

Differences in the Inhibition of Cytochromes P450 3A4 and 3A5 by Metabolite-Inhibitor Complex Forming Drugs
     Donovan J. McConn, Univ. of Washington

Identification of 1, 25-dihydroxyvitamin D3 as a novel endogenous substrate for cytochrome P450 3A4
     Yang Xu, Univ. of Washington

Cytochrome P450s metabolize endogenous and exogenous aldehydes
     Immaculate Amunom, Univ. of Louisville Sch. of Med.

A polymorphic UGT2B17 gene deletion and its correlation with NNAL glucuronidation phenotype in human liver microsomes
     Philip Lazarus, Penn State Col. of Med.

Genetic Susceptibility to Estrogen Carcinogenesis
Chairs: Judy L. Bolton and Terrence K. Monks
(Sponsored by the Division for Toxicology and the Committee on Women in Pharmacology)
Convention Center, Room 9

Findings of the Women's Health Initiative
     Sylvia Wassertheil-Smoller, Albert Einstein Col. of Med.

Epigenetic variation in prostate tumorigenesis after phytoestrogen exposure
  Dennis B. Lubahn, Univ. of Missouri-Columbia

Genetic polymorphism in catechol-O-methyltransferase (COMT) and endogenous catechol estrogen exposure:  Role in breast cancer risk?
     James D. Yager, Johns Hopkins Univ.

Catechol-O-methyltransferase (COMT) polymorphism in equine estrogen carcinogenesis
     Judy L. Bolton, Univ. of Illinois at Chicago Col. of Pharm.

Pharmacology and Phenotype:  Comparing Effects of Drug Antagonists with Gene Knockouts In Vivo

Chairs:  S. Barak Caine and Linda A. Dykstra
(Sponsored by the Divisions for Behavioral Pharmacology and Neuropharmacology)
Convention Center, Room 5B

Functional studies with drugs and knockouts: Regulatory systems beyond the cell surface
     Laura M. Bohn, Ohio State Univ.

Drugs and knockouts for 5-HT receptor subtypes: Measures of behavior and neurotransmitter release in vivo
     Loren H. Parsons, Scripps Res. Inst.

Phenotypes of NR1 knockdown mice: Comparison with effects of NMDA antagonists in C57BL/6J mice
     Linda A. Dykstra, Univ. of North Carolina at Chapel Hill

Drugs and knockouts for dopamine receptor subtypes: Focus on behavioral effects of psychomotor stimulants
     S. Barak Caine, McLean Hosp./Harvard Med. Sch.

Effects of dopamine D2/3 ligands on cocaine discrimination in dopamine D3 receptor KO and WT mice
     Matthew O’Callaghan, NIDA, NIH

Alterations in the antinociceptive and conditioned effects of morphine and cocaine in muscarinic acetylcholine receptor 1 (M1) deficient mice
     Kelly Carrigan, Univ. of Carolina at Chapel Hill

Wednesday Afternoon - There is no Wednesday afternoon programming

Division Sessions (to date)

Monday Afternoon (3:00 pm - 5:30 pm)

Division for Drug Discovery, Drug Development & Regulatory Affairs Symposium:
     Therapeutic Agent-Device Combinations
       Chair:  Tom J. Parry
       Convention Center, Room 4 

Preclinical development of drug-coated stents
     Gregory A. Kopia, Cordis Corp., Warren, NJ

Clinical development of drug-coated stents
     Pedro A. Lemos, Univ. of Sao Paolo, Brazil

Stem cell therapy for cardiac diseases
     Guilherme Silva, Texas Heart Inst., Houston

Regulation of combination device products
     Mirjam van Werven, Cordis, Corp., Miami Lakes, FL

Division for Behavioral Pharmacology Symposium:
     Preclinical Assessment of Pain and Analgesic Drugs
     Chair:  S. Steve Negus
      Convention Center, Room 5A

Preclinical models of acute pain
     Edward J. Bilsky, Univ. of New England

Preclinical models of inflammatory pain
     Todd W. Vanderah, Univ. of Arizona

Preclinical models of neuropathic pain
     Michael R. Brandt, Wyeth Disc. Res., Princeton, NJ

Targeting pain-suppressed behaviors in preclinical models of pain and analgesia
     S. Steve Negus, McClean Hospital, Harvard Med. Sch.

Use of fMRI for drug development in pain and analgesia
     David Borsook, McClean Hospital, Harvard Med. Sch.

Division for Cardiovascular Pharmacology Graduate Student and Postdoctoral
    Scientist Best Paper Competition
     Chair: John C. Kermode
     Marriott Hotel, Marina D

      Graduate Student Presentations:

 Contribution of cPLA₂ and PLD₂-regulated Akt activation to Ang II-induced vascular smooth muscle cell growth during injury
      Fang Li. Univ. of Tennessee Hlth. Sci. Ctr. (Advisor: Kafait Malik)

Activation of estrogen receptor alpha protects the in vivo rabbit heart from ischemia-reperfusion injury
     Erin A. Booth. Univ. of Michigan Med. Sch. (Advisor: Ben R. Lucchesi)

Mn-SOD deficient mice exhibit increased oxidative stress and vascular dysfunction with aging
     Kathryn A. Brown. Univ. of Iowa Col. of Med. (Advisor: Frank M. Faraci)

Cloning and identification of the porcine A1 adenosine receptor mediating a novel mitogenic action of adenosine in coronary artery smooth muscle cells
     Jianzhong Shen. Univ. of Missouri-Columbia (Advisors: Michael Sturek (now Indiana Univ. Sch. of Med.) and Peter Wilden)

      Postdoctoral Presentations:

Role of sphingosine kinase in endothelial barrier protection
     Melissa L. Brannen. Univ. of Illinois at Chicago (Advisors: Denise Goodman, Children’s Memorial Hosp. and Dolly Mehta,
     Univ. of Illinois at Chicago)

Epoxyeicosatrienoic acid-dependent TRPV4 activation increases spontaneous transient outward current frequency in cerebral arterial smooth muscle
     Scott Earley. Univ. of Vermont Col. of Med. (Advisor: Joseph Brayden)

Antioxidant N-acetylcysteine (NAC) attenuates PKC-β2 and connective tissue growth factor (CTGF) overexpression and myocardial hypertrophy in diabetic rats
     Zhengyuan Xia. Univ. of British Columbia (Advisor: John H. McNeil)

Division for Drug Metabolism Workshop:
     Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB) and the Scientific
     Community:  An Interactive Workshop
       Chairs.  Timothy S. Tracy and David S. Riddick
       Marriott Hotel, Marina E

Navigating PharmGKB: Hands-on experience
     Teri E. Klein, Stanford Univ.

PharmGKB: What can it do for me?
     Russell B. Altman, Stanford Univ. Med. Ctr.

Pharmacogenetics of CYP2C9 inhibition and activation
     Timothy S. Tracy, Univ. of Minnesota

Pharmacogenetics of FMO1 and FMO3
     Ronald N. Hines, Med. Col. of Wisconsin

N-acetyltransferase pharmacogenetics and adverse reactions to sulfonamides
     Craig K. Svensson, Univ. of Iowa Col. of Pharmacy & Hlth. Sci.

Tuesday Afternoon (3:00 pm - 5:30 pm)

Division for Molecular Pharmacology Postdoctoral Awards Finalists
      Marriott Hotel, Marina E

Division for Neuropharmacology Symposium:
     The Ten Commandments of Pharmacology:  Does Functional Selectivity/Agonist Trafficking Make
     Nothing Sacred?
     Chair:  Richard B. Mailman
      Convention Center, Room 2

Introduction: Are pharmacology’s ten commandments still viable? How functional selectivity affects teaching and research. 
     Richard B. Mailman, Univ. of North Carolina at Chapel Hill

Evidence and mechanisms of ligand-dependent functional selectivity in GPCRs from a structural perspective
     Harel Weinstein, Weill Med. Col., Cornell Univ.

Conformational changes at the dimer interface are associated with receptor activation
   Jonathan A. Javitch, Columbia Univ. Col. of Physicians and Surgeons

Is functional selectivity an artifact of in vitro systems?
   Bryan L. Roth, Case Western Reserve Univ. Sch. of Med.

Classifying drugs and receptors:  Past, present, and future
   Michael Spedding, Inst. de Recherches Servier, Suresnes, France

Message in a model: Receptor theory as a tool for studying functional selectivity
   Arthur Christopoulos, Univ. of Melbourne, Parkville, Victoria, Australia

Functional selectivity: Is it real and does it affect drug discovery?
   Keith J. Miller, Bristol-Myers Squibb

Panelists: 
David R. Sibley, NINDS, NIH
William P. Clarke, Univ. of Texas Hlth. Sci. Ctr. at San Antonio
Mark von Zastrow, UCSF
David E. Nichols, Purdue Univ. Sch. of Pharm. & Pharmaceut. Sci.
Richard B. Mailman, Univ. of North Carolina at Chapel Hill Med. Sch.
Brian K. Kobilka, Stanford Univ. Med. Ctr.

Division for Systems and Integrative Pharmacology Symposium:
     20 Years of Calcium Imaging:  A Revolution in Cell Physiology to Dye For
      Chairs:  Ismail Laher and Harm J. Knot
      Convention Center, Room 5A 

Keynote Lecture: Calcium as a master switch
  Roger Y. Tsien, UCSD Sch. of Med.

Calcium and striated muscle
   W. Jonathan Lederer, Univ of Maryland

Calcium regulates cell secretion
   Ole H. Petersen, Univ. of Liverpool

Calcium and smooth muscle contraction
   Mark T. Nelson, Univ. of Vermont

Calcium regulates endothelial cell function
   Wolfgang F. Graier, Univ. of Graz, Austria

Division for Toxicology Symposium:

     Role of Mitochondria in Toxic Oxidative Stress
     Chair: Marc W. Fariss
     Convention Center, Room 4

Role of mitochondrial vitamin E in toxic oxidative stress
   Marc W. Fariss, Univ. of Colorado Hlth. Sci. Ctr.

Role of mitochondrial DNA in toxic oxidative stress
   Ben Van Houten, NIEHS, NIH, Research Triangle Park, NC

Role of cardiolipin in toxic oxidative stress
   Sten Orrenius, Karolinska Inst., Stockholm, Sweden

Role of mitochondrial aconitase in toxic oxidative stress
   Manisha Patel, Univ. of Colorado Hlth. Sci. Ctr.

Role of mitochondrial uncoupling protein 2 in pathogenesis of type 2 diabetes
   Catherine B. Chan, Atlantic Vet. Col., Univ. of Prince Edward Is.

Division for Clinical Pharmacology Symposium:
     Pharmacological Rationale for COX-2 Adverse Effects: Scientific and Regulatory Lessons Learned?
       Chairs:  David A. Flockhart and Darrell R. Abernethy
       Room: Convention Center, Room 5B 

The cardiovascular biology of cyclooxygenase-2.
   Garret A. Fitzgerald, Univ. of Pennsylvania
   Alastair J.J.Wood, Vanderbilt Univ. Sch. of Med.

Special Sessions

Friday and Saturday

Behavioral Pharmacology Society Meeting (6:00pm Friday - 7:00pm Saturday)

Separate Registration
For program and registration information, contact Charles P. France

Saturday Afternoon (1:00 pm - 6:30 pm)

Graduate Student Colloquium
Drug Development at the Edge:  What Every Pharmacologist Should Know About Intellectural Property, Licensing, Startups and Venture Capital
Chair:  Edward Bilsky
Convention Center, Room 3

Introduction
    Edward Bilsky, University of New England

 

So You Want to Start a Biotech I.  An Academic Scientist's Experience

     Robert Dorr, University of Arizona

 

So You Want to Start a Biotech II.  Business Plans, Fundraising and More

     Karin Gregory, Dover Medical Ventures

 

Why Tech Transfer Officers are an Academic Scientist's Best Friend"  Protecting Your Intellectual Property

     Mary Louise Trammell, University of Arizona

 

Big Pharma and the Licensing Process:  What You Need to Know

     Elizabeth Bachert, Pfizer, Inc.

 

Academic and industry scientists are working together more and more frequently as apart of the drug development process.  Furthermore, many academic pharmacologists are beginning to be part of biotechnology startup companies that license technology to the larger pharmaceutical companies (or are consulting/contracting for these companies).  Graduate programs typically do not offer formal training in the practical aspects of protecting intellectual property, licensing technology, working with industry partners, and/or starting up ones own biotechnology company.  This is unfortunate in that having a solid appreciation of the many issues that will likely arise is critical to the success of the endeavors.

2005 Teaching Institute
Let's Get Integrative:  Finding Jobs in Industry

Chairs: Barbara  S. Beckman, Edward J. Bilsky and George J. Christ
(Sponsored by the Division for Pharmacology Education, the Graduate Recruitment and Education Committee and the Committee on Public Affairs)
Convention Center, Room 2

Attendees will hear from industry representatives about opportunities that exist for those individuals trained in the use of intact organ systems and in vivo animal models. For those scientists with a background in integrative organ system biology, there are good jobs available.  Find out what skills and background are needed and what opportunities exist.  Industry representatives will visit the breakout groups and discuss what needs and skills they look for and what opportunities exist within their companies.

Academic perspectives on the training of integrative whole organ scientists
  Edward D. French, Univ. of Arizona

Breakout Sections
Attendees will meet with each of the industry representatives to learn about the skills and training needed to obtain research positions at their companies looking for scientists with strong integrative and in vivo, whole organ systems background

Srinivas G. Rao, Cypress Bioscience, Inc.
Gerald J. Schaefer, WIL Research Labs., Inc.
Christopher F. Toombs, Amgen, Inc.
Bryan F. Cox, Abbott Laboratories
Euan MacIntyre, Merck Research Labs

Sunday Morning

Minorities Committee Workshop
Effective Communication for Scientific Success
Chairs: Ashiwel S. Undie and Martha I. Davila-Garcia
Marriott Hotel, Marriott Hall 2

Welcome comments on behalf of sponsoring committees and programs
  Margarita L. Dubocovich, Northwestern Univ.

Overview of communication modes and media
  Ashiwel S. Undie, Univ. of Maryland Sch. of Pharm.

A personal experience with communication
  Martha I. Davila-Garcia, Howard Univ.

Communication principles for effective scientific writing
  Stephanie W. Watts, Michigan State Univ.

Communication practices for effective presentations and teaching
  Richard Dalby, Univ. of Maryland Sch. of Pharm.

Communication approaches in steering a mentoring relationship
  Joan Y. Reede, Harvard Med. Sch.

Communication techniques for productive networking and collaboration
  Floyd E. Bloom, Scripps Res. Inst.

Short Course
Introduction to Cardiovascular Pharmacology:  Focus on Pathophysiology and Therapeutic Interventions
Chair:  Benedict R. Lucchesi
Convention Center, Room 3

Cardiac electrophysiology and arrhythmogenesis
  Benedict R. Lucchesi, University of Michigan

 

Introduction to the electrocardiogram
  Peter S. Fischbach, University of Michigan

 

Drug-induced malignant ventricular tachycardia (TdP): A major safety pharmacology issue in drug selection, development and registration
  Icilio Cavero, Senior Research Advisor, Italy

 

WEB LInks

Sunday Afternoon

Refresher Course: Pharmacokinetics
Chair:  Juan J.L. Lertora

(Sponsored by the Division for Pharmacology Education)
Convention Center, Room 4

So, you’re teaching Pharmacokinetics for the first time, or want a refresher of the principles?   Dr. Juan Lertora, a clinical pharmacologist from Tulane, will demonstrate tips and techniques for efficiently teaching this topic to medical students.  Audience discussion will solicit other successful approaches. Teaching materials will be made available.

Monday Morning

ASPET Women in Pharmacology/APS Women in Physiology Committees Workshop
Managing a Laboratory
Chairs:  Lynn Wecker and Siribhinya Benyajati

Marriott Hotel, Marina D

Managing a laboratory: Its role in success or failure
    Lynn Wecker, Univ. of South Florida

Mentoring vs. supervising
     Sue P. Duckles. UCI

How to delegate and still stay on top of things
Carol A. Paronis. McLean Hosp., Harvard Med. Sch.

Conflict management or managing difficult employees
     Virginia M. Miller. Mayo Clinic Col. of Med.

Developing a budget
     Stephanie W. Watts. Michigan State Univ.

Breakout Sessions

• Interviewing tips (Carol Paronis/Michelle Kalis)
• Performance reviews (Margaret Kolka/Kathy Berecek)
• Stimulating students in a healthy, competitive environment (Jody Krontiris-Litowitz)
• Dealing with conflicts/romance in the lab (Siribhinya Benyajati/Ann Schreihofer)
• Can a supervisor be a friend? (Lynn Wecker/Pat Sonsalla)
• Small group workshop on creating budgets (Carol Liedtke/Beth Levant)

Tuesday Morning (9:30 am - 12:00 noon)

Short Course
Lipid Signaling Pathways and Paradigms
Chairs: Kathryn E. Meier and Kevin R. Lynch
Marriott Hotel, Marina E

Phosphatidylcholine metabolism
  Andrew J. Morris, Univ. of North Carolina at Chapel Hill

Phosphatidylinositol metabolism
  Michael Wakelam, Birmingham Univ. Med. Sch., Birmingham, UK

Sphingolipid metabolism
  Alfred H. Merrill, Jr., Georgia Inst. of Tech.

Eicosanoid metabolism
  Jilly Evans, Merck & Co.

Lectures 

Ray Fuller Lecture in the Neurosciences: Randy D. Blakely, Vanderbilt University
 Monday,  8:15 am - 9:15 am
 Convention Center, Room 2
Neurotransmitter Transporters on the Rise:  Modulation of Synaptic Uptake Systems

Torald Sollmann Award Lecture:  Kenneth E. Moore, Michigan State University
  Sunday, 1:30 pm - 2:30 pm
  Convention Center, Room 3
 Pharmacology: Not Just a Job

General Information

Awards

Call for Abstracts

Hotels

Registration